Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desipramine + propranolol is a combination of two small molecule drugs, each with distinct mechanisms of action. Desipramine is a tricyclic antidepressant (TCA) primarily used to treat depression; it acts mainly by inhibiting the reuptake of norepinephrine and, to a lesser extent, serotonin in the central nervous system. Propranolol is a non-selective beta-adrenergic antagonist (beta blocker) used for hypertension, angina, arrhythmias, migraine prophylaxis, and other cardiovascular conditions. The combination does not have an established unique indication or brand formulation but may be co-administered in clinical practice for patients requiring both antidepressant and cardiovascular therapy. Pharmacodynamic interactions are possible; desipramine can antagonize some presynaptic effects of propranolol on noradrenaline release[2][3][4]. Both drugs are metabolized by hepatic enzymes and may interact at the level of drug metabolism[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desipramine + propranolol.